Skip to main content

Table 2 Subgroup analysis for the effect of statin therapy on cardiovascular disease

From: Effect of statins on cardiovascular events in patients with mild to moderate chronic kidney disease: a systematic review and meta-analysis of randomized clinical trials

Subgroup Value Reference Statin Control Relative risk (95% CI) p value Heterogeneity p value for heterogeneity
    (Event/total) (Event/total)     
Mean Age > = 60 14,27-29,31-33 853/7119 1211/7223 0.72 [0.65, 0.79] <0.001 21.2% 0.27
  <60 23-25 1614/8856 2042/8925 0.80 [0.75, 0.84] <0.001 0% 0.50
Cardiovascular History Yes 28-29,31,34 498/2417 712/2489 0.72 [0.65, 0.80] <0.001 0% 0.49
  No 14,25-26, 32 404/6842 544/6998 0.73 [0.60, 0.88] 0.001 27.6% 0.25
Diabetes Yes 27-28,34 173/1334 260/1424 0.74 [0.63, 0.88] <0.001 0% 0.94
  No 25,27-28,32-34 329/3123 484/3129 0.68 [0.59, 0.79] <0.001 10% 0.35
Baseline GFR > = 60 23,26,28 1914/13046 2481/13280 0.77 [0.71, 0.83] <0.001 21.9% 0.28
  <60 25,29, 32-33 128/2116 203/2127 0.62 [0.47, 0.83] 0.001 29.4% 0.24
Baseline Creatinine > = 1.5 25,29 80/333 111/339 0.71 [0.45, 1.12] 0.139 11.6% 0.29
  <1.5 23,24,28,31-32 1869/10241 2430/10367 0.73 [0.63, 0.84] <0.001 48.0% 0.10
Baseline Total Cholesterol > = 5.0 23,28 1816/9513 2337/9527 0.77 [0.70, 0.84] <0.001 35.6% 0.21
  <5.0 24-25,29,31-34 344/3543 509/3585 0.69 [0.60, 0.80] <0.001 18.1% 0.29
Baseline LDL Cholesterol > = 3.0 23-25,27-29, 31-32 2131/11220 2809/11389 0.74 [0.70, 0.81] P < 0.001 29.0% 0.20
  <3.0 14,30,33 825/6357 1018/6264 0.76 [0.72, 0.81] P < 0.001 37.7% 0.20
LDL Cholesterol Lowering > = 30% 14,23,26,28,29,33 2328/18087 3030/18332 0.77 [0.73, 0.82] P < 0.001 10.4% 0.35
  <30% 24,25,32 32/625 52/636 0.76 [0.71, 0.82] 0.087 35.4% 0.21
Follow Up > = 3 14,23-24, 26–29,31-32 2523/17823 3320/18136 0.76 [0.72, 0.81] P < 0.001 14.4% 0.31
  <3 25,33 42/1685 77/1675 0.74 [0.69, 0.80] 0.001 0% 0.51
  1. Abbreviations: CI confidential interval, GFR glomerular filtration rate, LDL low density lipoprotein.